BOSTON, Oct. 23 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global bio/pharmaceutical services organization, today announced the formation of a strategic alliance with e-tractions to enhance the Internet marketing services provided through its Medical Communication Services business unit. Through the alliance with e-tractions, PAREXEL Medical Communication Services provides a broader portfolio of Internet solutions to help clients achieve their marketing goals more efficiently.
"PAREXEL is pleased to incorporate the outstanding Internet marketing capabilities of e-tractions into our world-class medical communication services and existing website design and development capabilities," said Glenn C. Van Deusen, Corporate Vice President and Worldwide Head, PAREXEL Medical Communication Services. "E-communication and the Internet are playing an increasing role in healthcare communications, and our alliance with e-tractions reinforces our commitment to continually find better ways to meet the needs of our clients, and enable them to provide information about their products in a range of media."
"We look forward to working seamlessly with PAREXEL to contribute our award-winning Internet marketing capabilities to achieve success for their clients' businesses, whether through online marketing campaigns, lead generation efforts or marketing performance management programs," said Michael Gauthier, Founder and CEO, e-tractions.
PAREXEL Medical Communication Services, which offers expertise in a broad range of therapeutic areas, helps clients translate clinical data and complex scientific knowledge into motivating communication materials and services and continuing medical education programs to turn healthcare discoveries into market successes. The PAREXEL Medical Communication Services business units, with over 500 employees worldwide, develop medical writing and communications, meetings/events/exhibits, creative services, reimbursement/patient assistance programs, educational services, and scientific publications.
About e-tractions
e-tractions provides Internet marketing solutions for both business-to-business and business-to-consumer applications regardless of industry. Economic conditions and consumer behavior are driving companies of all sizes to the Internet to most efficiently reach their sales and marketing goals. Launched in 1999, e-tractions has developed hundreds of online marketing programs in the pharmaceutical, technology, consumer and not-for-profit industries. For more information about e-tractions visit http://www.e-tractions.com.
About PAREXEL
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and integration services. Headquartered near Boston, Massachusetts, PAREXEL operates in 51 locations throughout 40 countries around the world, and has approximately 5,600 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the amendment or interpretation of Financial Accounting Standards Board Statement No. 123 (revised 2004), Share-Based Payment ("Statement 123R"), which could change the Company's current assessment of the effects of the adoption of Statement 123R on the acceleration of equity grants, the assumptions inherent in equity pricing models under Statement 123R and the final results of the closing of the Company's books for future financial periods; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-K for the period ended June 30, 2006 as filed with the SEC on September 8, 2006, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward- looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Contacts: Jill Baker Jennifer Baird Vice President, Investor Relations Director of Public Relations Tel: 781-434-4118 Tel: 781-434-4409 Email: Jill.Baker@PAREXEL.com Email: Jennifer.Baird@PAREXEL.com
PAREXEL International CorporationCONTACT: Jill Baker, Vice President, Investor Relations, +1-781-434-4118,Jill.Baker@PAREXEL.com, or Jennifer Baird, Director of Public Relations,+1- 781-434-4409, Jennifer.Baird@PAREXEL.com, both of PAREXEL InternationalCorporation
